Viewing data from:

ERGAMISOL

NDA

LEVAMISOLE HYDROCHLORIDE | N020035 | JANSSEN PHARMACEUTICA PRODUCTS LP

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain0 active DMFs1 inactive

0 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

JANSSEN PHARMACEUTICA NVInactiveLEVAMISOLE HYDROCHLORIDE CRUDE

DMF 109951994

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 50MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jun 18, 1990

No patent or exclusivity listings for this strength.